Specialized Care
Evidence-based articles on Specialized Care โ conditions, diagnostic approaches, treatments and what to expect from China's specialist hospitals.
Cancer Treatment in China: What to Confirm Before You Travel
There is no fixed price, and an approval is not eligibility. Confirm a written plan, the biomarker question, an itemised estimate and the records a hospital still needs before you book.
Genetic Testing in China: What to Verify Before a Sample Is Taken
A lower fee or a busy laboratory does not tell you whether a genetic test is the right one. Confirm the laboratory, the assay, the specimen, the written quote and whether a doctor at home can use the report.
Innovation Drug Access in China: Three NMPA Approvals, Reviewed in October 2026
As of 6 October 2026, three mainland China decisions show different routes from an NMPA authorisation to treatment: a CLDN18.2 CAR-T for a defined gastric-cancer population, a pirtobrutinib label covering CLL/SLL across lines of therapy, and a new 11.25 mg leuprorelin microsphere strength. Approval is not the same thing as a hospital appointment or an individual bill.
AI-Assisted Care in China Hospitals: What International Patients Should Confirm
AI in Chinese hospitals usually supports imaging and workflow, not an autonomous diagnosis. What varies by hospital, what a physician-signed report means, and what PriumCare confirms in writing before recommending a scan.
Ready to arrange treatment in China?
Our care navigators provide English-language coordination for consultations, diagnostics and procedures at China's leading hospitals.